<DOC>
	<DOC>NCT00238472</DOC>
	<brief_summary>This study is not being conducted in the United States. The purpose of the study is to evaluate the effects of nateglinide compared to glibenclamide on renal hemodynamics and albumin excretion.</brief_summary>
	<brief_title>A Pilot Study to Evaluate the Effects of Nateglinide vs. Glibenclamide on Renal Hemodynamics and Albumin Excretion</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Nateglinide</mesh_term>
	<mesh_term>Glyburide</mesh_term>
	<criteria>Type 2 diabetes diagnosed at least 1 year before inclusion Blood glucose criteria must be met Microalbuminuria criteria must be met Pregnant or nursing females or females of childbearing potential not using a medically approved birth control method Blood glucose criteria outside the specified range Microalbuminuria criteria outside the specified range Serious cardiovascular events within the past 6 months Other protocoldefined exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>nateglinide</keyword>
</DOC>